Department of Anatomy and Cell Biology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada 7E3 5E5.
BMC Cancer. 2011 Jul 13;11:293. doi: 10.1186/1471-2407-11-293.
Integrins are used as prognostic indicators in breast cancer. Following engagement with extracellular matrix proteins, their signaling influences numerous cellular processes including migration, proliferation, and death. Integrin signaling varies between cell types through differential expression of integrin subunits, and changes within a given cell upon exposure to a cell agonist or through changes in its surroundings. These variations in signaling can profoundly affect the phenotypic, tumorogenecity and metastatic properties of cancer cells. In the present study, we investigated if there were differences in the expression of integrins, integrin structures, and integrin co-receptors within three breast cancer cells and if these differences effected integrin signaling.
Expression of integrins, urokinase receptor and vascular endothelial cell growth factor receptor (VEGFR) in metastatic MDA-MB-435 and MDA-MB-231, non-metastatic MCF7 and non-breast cancer Hek-293 cells was measured by flow cytometry. Cell adhesion was assessed using collagen, fibrinogen, fibronectin and vitronectin coated plates. Changes in kinase levels following PMA stimulation, and cell adhesion-induced activation of kinases were determined by western blot analysis. Distribution of actin stress fibers and focal adhesions was assessed by immunocytochemistry.
All cells expressed αv integrins, while high β5 and αvβ5 expression was restricted to the cancer cells and high β3 and αvβ3 expression was restricted to MDA-MB-435 cells. The two metastatic cells were the least adhesive, but all cells adhered well to most proteins in the absence of PMA. All proliferating cells expressed activated pSrc, but only proliferating metastatic cells expressed high pMEK levels. PMA treatment resulted in time-dependent changes in activated kinase levels, and only MDA-MB-231 cells constitutively expressed high levels of activated pMEK. MDA-MB-435 cells formed more stress fibers and focal adhesions and only exhibited adhesion-induced activation of pMEK and pFAK. All cells expressed the urokinase receptor, but MCF7 cells had markedly higher VEGFR expression. Adhesion induced differential expression of pFAK, pMEK and pERK.
This study demonstrates that breast cancers vary in their expression of integrins, their capacity to form focal adhesion and to signal through integrins. These differences likely contribute to phenotypic variations between cancer lines and account for some of the heterogeneity of breast cancer.
整合素被用作乳腺癌的预后指标。与细胞外基质蛋白结合后,其信号影响包括迁移、增殖和死亡在内的多种细胞过程。整合素信号通过整合素亚基的差异表达以及在暴露于细胞激动剂或通过其周围环境变化时细胞内的变化在细胞类型之间变化。这些信号的变化可以深刻影响癌细胞的表型、肿瘤发生和转移特性。在本研究中,我们研究了三种乳腺癌细胞中整合素、整合素结构和整合素共受体的表达是否存在差异,以及这些差异是否影响整合素信号。
通过流式细胞术测量转移性 MDA-MB-435 和 MDA-MB-231、非转移性 MCF7 和非乳腺癌 Hek-293 细胞中整合素、尿激酶受体和血管内皮细胞生长因子受体 (VEGFR) 的表达。使用胶原、纤维蛋白原、纤维连接蛋白和 vitronectin 包被的平板评估细胞粘附。通过 Western blot 分析测定 PMA 刺激后激酶水平的变化和细胞粘附诱导的激酶激活。通过免疫细胞化学评估肌动蛋白应力纤维和焦点粘连的分布。
所有细胞均表达 αv 整合素,而高表达的 β5 和 αvβ5 仅限于癌细胞,高表达的 β3 和 αvβ3 仅限于 MDA-MB-435 细胞。这两个转移性细胞的粘附性最低,但在没有 PMA 的情况下,所有细胞都能很好地粘附在大多数蛋白质上。所有增殖细胞均表达激活的 pSrc,但只有增殖的转移性细胞表达高水平的 pMEK。PMA 处理导致激活激酶水平的时间依赖性变化,只有 MDA-MB-231 细胞持续表达高水平的激活 pMEK。MDA-MB-435 细胞形成更多的应力纤维和焦点粘连,仅表现出粘附诱导的 pMEK 和 pFAK 激活。所有细胞均表达尿激酶受体,但 MCF7 细胞 VEGFR 表达明显更高。粘附诱导 pFAK、pMEK 和 pERK 的差异表达。
本研究表明,乳腺癌在整合素表达、形成焦点粘连和整合素信号转导能力方面存在差异。这些差异可能导致癌症系之间表型的差异,并解释了乳腺癌的一些异质性。